- Home
- WFC vs MRK Comparison
WFC vs MRK Comparison
Compare WFC & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFC | MRK |
|---|---|---|
| Founded | 1852 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.6B | 268.7B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | WFC | MRK |
|---|---|---|
| Price | $78.89 | $116.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 14 |
| Target Price | $97.37 | ★ $123.21 |
| AVG Volume (30 Days) | ★ 14.5M | 9.1M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | 2.24% | ★ 2.94% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | N/A | ★ 7.28 |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | $11.46 | $3.74 |
| Revenue Next Year | $4.55 | $5.47 |
| P/E Ratio | ★ $14.15 | $15.92 |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $58.42 | $75.40 |
| 52 Week High | $97.76 | $125.14 |
Technical Indicators
Market Signals| Indicator | WFC | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 32.33 | 47.39 |
| Support Level | $77.38 | $105.23 |
| Resistance Level | $85.22 | $125.14 |
| Average True Range (ATR) | 2.79 | 2.80 |
| MACD | -0.61 | -1.20 |
| Stochastic Oscillator | 16.19 | 26.15 |
Price Performance
Historical ComparisonAbout WFC Wells Fargo & Company
Wells Fargo is one of the largest banks in the United States, with approximately $2.1 trillion in balance-sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US market.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).